Tag: Product hopping

In September 2013, the oral contraceptive Loestrin 24 Fe was abruptly discontinued by its manufacturer, Warner Chilcott. This decision was not made for safety reasons or because of any issues with the medication's effectiveness. Instead, the reason behind the question, 'Why was Loestrin 24 FE discontinued?', was a controversial 'product hopping' scheme that led to a major antitrust lawsuit.

In 2009, brand-name drug manufacturers Abbott Laboratories and Fournier Industrie et Sante settled a major class-action antitrust lawsuit for $250 million over the cholesterol drug fenofibrate (TriCor). For those asking **what is the lawsuit for fenofibrate**, the answer is not about a single case, but a series of legal challenges primarily focused on corporate misconduct and anticompetitive practices, not side effects.